| ［1］ |
Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review［J］. Int J Mol Sci, 2020,21（5）:1690. doi: 10. 3390/ijms21051690.
|
| ［2］ |
Fotiadou C, Lazaridou E. Psoriasis and uveitis: links and risks［J］. Psoriasis （Auckl）, 2019,9:91⁃96. doi: 10.2147/PTT.S179182.
|
| ［3］ |
Alsenaid A, Ezmerli M, Srour J, et al. Biologics and small molecules in patients with scalp psoriasis: a systematic review［J］. J Dermatolog Treat, 2020:1⁃10. doi: 10.1080/09546634.2020. 1770167.
|
| ［4］ |
Misiak⁃Galazka M, Zozula J, Rudnicka L. Palmoplantar pustulosis: recent advances in etiopathogenesis and emerging treatments［J］. Am J Clin Dermatol, 2020,21（3）:355⁃370. doi: 10.1007/s40257⁃020⁃00503⁃5.
|
| ［5］ |
Smith MP, Ly K, Thibodeaux Q, et al. Acrodermatitis continua of Hallopeau: clinical perspectives［J］. Psoriasis （Auckl）, 2019,9:65⁃72. doi: 10.2147/PTT.S180608.
|
| ［6］ |
Bardazzi F, Starace M, Bruni F, et al. Nail psoriasis: an updated review and expert opinion on available treatments, including biologics［J］. Acta Derm Venereol, 2019,99（6）:516⁃523. doi: 10.2340/00015555⁃3098.
|
| ［7］ |
Micali G, Verzì AE, Giuffrida G, et al. Inverse psoriasis: from diagnosis to current treatment options［J］. Clin Cosmet Investig Dermatol, 2019,12:953⁃959. doi: 10.2147/CCID.S189000.
|
| ［8］ |
Ollech A, Zvulunov A, Pavlovsky L, et al. Biologic treatment of recalcitrant pediatric psoriasis: a case series from a tertiary medical center［J］. J Dermatolog Treat, 2019,30（2）:152⁃155. doi: 10.1080/09546634.2018.1476655.
|
| ［9］ |
Bronckers I, Seyger M, West DP, et al. Safety of systemic agents for the treatment of pediatric psoriasis［J］. JAMA Dermatol, 2017,153（11）:1147⁃1157. doi: 10.1001/jamadermatol.2017.3029.
|
| ［10］ |
Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis［J］. N Engl J Med, 2008,358（3）:241⁃251. doi: 10.1056/NEJMoa066886.
|
| ［11］ |
Paller AS, Siegfried EC, Pariser DM, et al. Long⁃term safety and efficacy of etanercept in children and adolescents with plaque psoriasis［J］. J Am Acad Dermatol, 2016,74（2）:280⁃287. doi: 10.1016/j.jaad.2015.09.056.
|
| ［12］ |
Foeldvari I, Constantin T, Vojinović J, et al. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis⁃related arthritis, or psoriatic arthritis: 6⁃year efficacy and safety data from an open⁃label trial［J］. Arthritis Res Ther, 2019,21（1）:125. doi: 10.1186/s13075⁃019⁃1916⁃9.
|
| ［13］ |
鲁珊, 周薇, 张倩, 等. 幼年银屑病关节炎［J］. 中国当代儿科杂志, 2007,9（4）:339⁃342. doi: 10.3969/j.issn.1008⁃8830.2007. 04.014.
|
| ［14］ |
Hospach T, Glowatzki F, Blankenburg F, et al. Scoping review of biological treatment of deficiency of interleukin⁃36 receptor antagonist （DITRA） in children and adolescents［J］. Pediatr Rheumatol Online J, 2019,17（1）:37. doi: 10.1186/s12969⁃019⁃0338⁃1.
|
| ［15］ |
Papoutsaki M, Costanzo A, Mazzotta A, et al. Etanercept for the treatment of severe childhood psoriasis［J］. Br J Dermatol, 2006,154（1）:181⁃183. doi: 10.1111/j.1365⁃2133.2005.06982.x.
|
| ［16］ |
Fialová J, Vojáčková N, Vaňousová D, et al. Juvenile generalized pustular psoriasis treated with etanercept［J］. Dermatol Ther, 2014,27（2）:105⁃108. doi: 10.1111/dth.12065.
|
| ［17］ |
Armaroli G, Klein A, Ganser G, et al. Long⁃term safety and effectiveness of etanercept in JIA: an 18⁃year experience from the BiKeR registry［J］. Arthritis Res Ther, 2020,22（1）:258. doi: 10.1186/s13075⁃020⁃02326⁃5.
|
| ［18］ |
Papp K, Thaçi D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double⁃blind, phase 3 trial［J］. Lancet, 2017,390（10089）:40⁃49. doi: 10.1016/S0140⁃6736（17）31189⁃3.
|
| ［19］ |
Thaçi D, Papp K, Marcoux D, et al. Sustained long⁃term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double⁃blind, phase III study［J］. Br J Dermatol, 2019,181（6）:1177⁃1189. doi: 10.1111/bjd.18029.
|
| ［20］ |
Horneff G, Seyger M, Arikan D, et al. Safety of adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis, enthesitis⁃related arthritis, psoriasis, and crohn′s disease［J］. J Pediatr, 2018,201:166⁃175. doi: 10.1016/j.jpeds.2018.05.042.
|
| ［21］ |
Craiglow BG, Boyden LM, Hu R, et al. CARD14⁃associated papulosquamous eruption: a spectrum including features of psoriasis and pityriasis rubra pilaris［J］. J Am Acad Dermatol, 2018,79（3）:487⁃494. doi: 10.1016/j.jaad.2018.02.034.
|
| ［22］ |
Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate⁃to⁃severe plaque psoriasis: results of the randomized phase 3 CADMUS study［J］. J Am Acad Dermatol, 2015,73（4）:594⁃603. doi: 10.1016/j.jaad.2015.07.002.
|
| ［23］ |
Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate⁃to⁃severe plaque psoriasis in paediatric patients （≥ 6 to < 12 years of age）: efficacy, safety, pharmacokinetic and biomarker results from the open⁃label CADMUS Jr study［J］. Br J Dermatol, 2020,183（4）:664⁃672. doi: 10.1111/bjd.19018.
|
| ［24］ |
Magnolo N, Kingo K, Laquer V, et al. Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate to severe plaque psoriasis: 52⁃week results from a randomized trial［C/OL］//American Academy of Dermatology Virtual Meeting Experience（AAD VMX）, online, 2021［2021⁃10⁃19］. https://eposters.aad.org/abstracts/26860.
|
| ［25］ |
Bodemer C, Kaszuba A, Kingo K, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52⁃week results from a Phase 3 double⁃blind randomized, controlled trial［J］. J Eur Acad Dermatol Venereol, 2021,35（4）:938⁃947. doi: 10.1111/jdv.17002.
|
| ［26］ |
谢辉, 牛美丽, 王新慧, 等. 司库奇尤单抗治疗儿童银屑病六例疗效评价［J］. 中国麻风皮肤病杂志, 2021,37（3）:157⁃159,162. doi: 10.12144/zgmfskin202103157.
|
| ［27］ |
孙勇虎, 张福仁. 白介素17A拮抗剂治疗儿童银屑病一例并文献复习［J］. 中国麻风皮肤病杂志, 2021,37（1）:30⁃31,36. doi: 10.12144/zgmfskin202101030.
|
| ［28］ |
Paller AS, Seyger M, Alejandro Magariños G, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double⁃blind, placebo⁃controlled study in paediatric patients with moderate⁃to⁃severe plaque psoriasis （IXORA⁃PEDS）［J］. Br J Dermatol, 2020,183（2）:231⁃241. doi: 10.1111/bjd.19147.
|
| ［29］ |
Ferrara G, Losi M, D′Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study［J］. Lancet, 2006,367（9519）:1328⁃1334. doi: 10.1016/S0140⁃6736（06）68579⁃6.
|
| ［30］ |
Bagel J. Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis［J］. J Drugs Dermatol, 2011,10（4）:366⁃371.
|
| ［31］ |
Gambichler T, Tigges C, Scola N, et al. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks［J］. Br J Dermatol, 2011,164（6）:1383⁃1386. doi: 10.1111/j.1365⁃2133. 2011.10358.x.
|
| ［32］ |
Wolf P, Weger W, Legat FJ, et al. Treatment with 311⁃nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab⁃treated patients: a randomized intraindividual trial［J］. Br J Dermatol, 2012,166（1）:147⁃153. doi: 10.1111/j.1365⁃2133.2011.10616.x.
|
| ［33］ |
Lynde CW, Gupta AK, Guenther L, et al. A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept［J］. J Dermatolog Treat, 2012,23（4）:261⁃267. doi: 10.3109/09546634. 2011.607795.
|
| ［34］ |
Park KK, Wu JJ, Koo J. A randomized, ′head⁃to⁃head′ pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B （NB⁃UVB） phototherapy in obese psoriasis patients［J］. J Eur Acad Dermatol Venereol, 2013,27（7）:899⁃906. doi: 10.1111/j.1468⁃3083.2012.04611.x.
|
| ［35］ |
Cather JC, Crowley JJ. Use of biologic agents in combination with other therapies for the treatment of psoriasis［J］. Am J Clin Dermatol, 2014,15（6）:467⁃478. doi: 10.1007/s40257⁃014⁃0097⁃1.
|
| ［36］ |
Heinecke GM, Luber AJ, Levitt JO, et al. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center［J］. J Drugs Dermatol, 2013,12（10）:1098⁃1102.
|
| ［37］ |
Bissonnette R, Maari C, Barber K, et al. Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab［J］. J Eur Acad Dermatol Venereol, 2015,29（8）:1576⁃1581. doi: 10.1111/jdv.12943.
|
| ［38］ |
Downs AM. Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab［J］. Br J Dermatol, 2010,163（2）:433⁃434. doi: 10.1111/j.1365⁃2133.2010. 09832.x.
|
| ［39］ |
Hu Y, Chen Z, Gong Y, et al. A review of switching biologic agents in the treatment of moderate⁃to⁃severe plaque psoriasis［J］. Clin Drug Investig, 2018,38（3）:191⁃199. doi: 10.1007/s40261⁃017⁃0603⁃3.
|
| ［40］ |
Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double⁃blind, phase III NAVIGATE trial［J］. Br J Dermatol, 2018,178（1）:114⁃123. doi: 10.1111/bjd.15750.
|
| ［41］ |
Sator P, Richter L, Saxinger W, et al. Adalimumab in the treatment of moderate⁃to⁃severe chronic plaque psoriasis in patients switching from other biologics［J］. J Eur Acad Dermatol Venereol, 2015,29（9）:1742⁃1749. doi: 10.1111/jdv.12981.
|
| ［42］ |
Lansang P, Bergman JN, Fiorillo L, et al. Management of pediatric plaque psoriasis using biologics［J］. J Am Acad Dermatol, 2020,82（1）:213⁃221. doi: 10.1016/j.jaad.2019.05.056.
|
| ［43］ |
Smith CH, Yiu Z, Bale T, et al. British association of dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update［J］. Br J Dermatol, 2020,183（4）:628⁃637. doi: 10.1111/bjd. 19039.
|
| ［44］ |
Menter A, Strober BE, Kaplan DH, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with biologics［J］. J Am Acad Dermatol, 2019,80（4）:1029⁃1072. doi: 10.1016/j.jaad.2018.11.057.
|
| ［45］ |
Huber F, Ehrensperger B, Hatz C, et al. Safety of live vaccines on immunosuppressive or immunomodulatory therapy⁃a retrospective study in three Swiss Travel Clinics［J］. J Travel Med, 2018,25（1）. doi: 10.1093/jtm/tax082.
|
| ［46］ |
Snast I, Atzmony L, Braun M, et al. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature［J］. J Am Acad Dermatol, 2017,77（1）:88⁃97. doi: 10.1016/j.jaad.2017.01.037.
|
